NCT00732147View on ClinicalTrials.gov

Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2009

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Type 2 Diabetes
Interventions
DRUG

Pramlintide acetate

120 micrograms given subcutaneously before each meal X 3.

DRUG

Placebo

120 micrograms given subcutaneously before each meal x 3.

Sponsors
All Listed Sponsors
collaborator

Amylin Pharmaceuticals, LLC.

INDUSTRY

lead

University of Maryland, Baltimore

OTHER